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In 2014, the US Food and Drug Administration (FDA) proposed to regulate laboratory-developed tests (LDTs)—diagnostics de-
signed, manufactured, and used within a single laboratory. The Infectious Diseases Society of America, the American Society for
Microbiology, and the Pan American Society for Clinical Virology recognize that the FDA is committed to protecting patients.
However, our societies are concerned that the proposed regulations will limit access to testing and negatively impact infectious
diseases (ID) LDTs. In this joint commentary, our societies discuss why LDTs are critical for ID patient care, hospital infection
control, and public health responses. We also highlight how the FDA’s proposed regulation of LDTs could impair patient access to
life-saving tests and stifle innovation in ID diagnostics. Finally, our societies make specific recommendations for the FDA’s con-
sideration to reduce the burden of the proposed new rules on clinical laboratories and protect patients’ access to state-of-the art,
quality LDTs.
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In October 2014, the US Food and Drug Administration (FDA) re-
leased draft guidance proposing to regulate laboratory-developed
tests (LDTs). The FDA proposes a risk-based approach, where
first high-risk and then moderate-risk test oversight is phased in
over a 9-year period. The FDA proposes 3 regulatory oversight ex-
emptions: tests for rare diseases (defined as <4000 tests performed
annually nationwide), tests for unmet clinical needs (where there is
no FDA-cleared or -approved test), and finally tests for “traditional”
LDTs that satisfy the FDA guidance definition (The FDA defines
LDTs as an “in vitro diagnostic that is intended for clinical use and
is designed, manufactured, and used within a single laboratory”) of
an LDT.
The Infectious Diseases Society of America (IDSA), the Amer-
ican Society for Microbiology (ASM), and the Pan American So-
ciety for Clinical Virology (PASCV) recognize that the FDA is
committed to protecting patient safety. The proposed regulations,
developed primarily out of concerns over oncology and genetic
testing, will have wide-reaching impact on all clinical laboratories.
Our societies are concerned that infectious diseases (ID) LDTs,
which have little evidence of providing unreliable results that
lead to harmful patient care decisions, are not being appropriate-
ly considered by the FDA’s proposed regulations. Many ID LDTs
have a long history of safe and effective use in patient care, and
our societies firmly believe the risks posed by ID LDTs are
dwarfed by their advances and benefits to patient care. IDSA,
ASM, and PASCV submitted comments to the FDA’s draft guid-
ance in early 2015, and an additional point-counterpoint on the
draft guidance was published in ASM’s Journal of Clinical Micro-
biology. With the expected release of the final guidance this year,
our societies would like to once again highlight the unique con-
cerns surrounding ID LDTs, and submit recommendations to
minimize disruptions limiting patient access to life-saving testing.
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THE IMPORTANCE OF ID LDTS
ID physicians care for patients of all ages with serious, often
life-threatening infections. Time is of the essence in ID patient
care, where even a few hours’ delay can negatively impact a pa-
tient’s outcome. To rapidly administer appropriate treatment
for infectious illnesses, physicians rely on laboratories to
provide clinically relevant diagnostic test results, from both
commercial in vitro diagnostics (IVDs) and LDTs, to not only
identify the cause of infection but also guide therapeutic selec-
tion. Local testing is especially important at major medical cen-
ters that specialize in transplantation and the management of
complex, critically ill patients, where physician and clinical lab-
oratory scientists regularly develop LDTs to keep pace with
newly emerging diseases. ID diagnostics also help protect the
broader public health by alerting health officials of the need
to trigger protocols to contain outbreaks and prevent the trans-
mission of ID. Last, these tests are vital for guiding clinicians’
stewardship of antimicrobial drugs to limit the development
of drug resistance as well as enhance hospital infection preven-
tion efforts.
IDSA, ASM, and PASCV support the need to ensure that
LDTs are safe and effective tools for the management of pa-
tients. However, our societies remain extremely concerned
that the FDA’s proposed regulations will create serious barriers
that could impede patient access to existing high-quality LDTs
and also threaten the innovation needed to keep pace with con-
stantly changing and emerging pathogens. The proposed pre-
market review requirements for clinical laboratories are
identical to IVD manufacturers for the clearance or approval
of tests. This will likely create a major, and in many cases, im-
possible challenge for individual clinical laboratories that are al-
ready addressing budgetary restrictions from declining
reimbursement. These requirements would be so prohibitive
of financial and administrative resources that clinical laborato-
ries would be unable to navigate a moderate-risk submission for
even one LDT in use, let alone the significantly higher require-
ments for a high-risk premarket approval (PMA) submission.
These challenges would likely force laboratories to discon-
tinue developing innovative LDTs and either move toward ex-
clusive use of commercial IVDs or send samples for testing to
outside reference laboratories. Both of these alternatives pose
considerable disadvantages. For example, commercial IVDs
are not yet available for the entire range of testing that are cur-
rently covered by LDTs, and additionally, a single vendor may
not be able to provide all tests required, forcing a laboratory to
make expensive investments in new instruments from multiple
companies to maintain its menu of testing. Commercial manu-
facturers may lag significantly in developing tests for emerging
or low-incidence diseases, putting patient safety and public
health at risk. Most importantly, sending clinical specimens to
reference laboratories for testing will significantly increase the
turnaround time required to get the results to physicians.
Rapid diagnostics that facilitate early initiation of life-saving
treatment are critical in ID patient care, where same-day results
can significantly improve patient outcomes. It is unlikely this
turnaround time can be achieved with outside testing by com-
mercial laboratories. The long-term consequences of LDT reg-
ulation could be an anticompetitive environment in which
broad LDT test menus that are currently available in many med-
ical centers are offered only by large regional for-profit com-
mercial reference laboratories.
IDSA, ASM, AND PASCV RECOMMENDATIONS
IDSA, ASM, and PASCV again offer specific recommendations
to improve the proposed regulatory framework and minimize
disruption of local, high-quality, ID testing for patient care.
Ensure the Standards Used to Assess the Clinical Validity of LDTs Are
Clear and Streamlined
The FDA’s draft proposal would require significant human and
financial resources. Clinical laboratories using LDTs would be
required to comply with standards designed for IVD manufac-
turers, including fees for submission, the expense of research
and development, and the ability to navigate complex FDA reg-
ulations, a task often performed by a manufacturer’s regulatory
affairs division. It is estimated that a “simple” 510(k) submis-
sion for a single test would cost between $2 million and $5 mil-
lion. Clearly, these costs are prohibitive for clinical laboratories
and healthcare institutions that are already economically
burdened.
It is critical that the FDA examine how it can increase flexi-
bility of moderate-risk premarket review for LDT clinical valid-
ity to better take into account the unique challenges clinical
laboratories will face during premarket submission. Our socie-
ties recommend that the FDA ensure that clinical validity can be
established by many sources, including peer-reviewed literature,
clinical guidelines, bench studies, data registries, postmarket
data, and clinical trials. We also recommend that the FDA ex-
amine data sharing models such as ClinGen, where evidence of
clinical validity can be “crowdsourced” from multiple laborato-
ries. Given that evidence may vary in quality, our societies offer
to provide expertise and guidance with assessing the quality of
these areas of evidence. For example, our societies can coordi-
nate with editors of major journals to identify guidelines on how
to assess the clinical validity of peer-reviewed literature.
Currently, the College of American Pathologists (CAP) and
the Clinical Laboratory Improvement Amendments (CLIA) reg-
ulations require that LDTs are analytically validated. Therefore, if
clinical validity is demonstrated by a similar commercial high-
risk test, clinical laboratories should not be required to redemon-
strate this via costly PMA submission. IDSA, ASM, and PASCV
also urge the FDA to allow LDTs that are high risk to be com-
pared analytically to high-risk approved devices as predicates.
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LDTs for ID Pathogens Should Have an Appropriate Prioritization
and Classification of Risk
A straightforward mechanism to assess and classify risk of
LDTs is critical. Our societies recommend that the FDA consid-
er past and present uses of LDTs, recognizing different patterns
of use in different disease areas, and noting both the benefits
that LDTs contribute to patient care as well as their potential
harm. The FDA should balance the risk associated with current
use of LDTs in each relevant disease area against the risk of cur-
tailing patient access to LDTs under the proposed regulations.
It is vital this process is completed in a timely fashion and is
as least burdensome to clinical laboratories as possible. Given
the importance of this process, IDSA, ASM, and PASCV
would like to offer its member expertise to serve on the
FDA’s review panels to develop an approach to classify LDT
risk. Furthermore, we would be pleased to help convene experts
to poll literature and other sources of information to identify
tests that have appropriately established safety and clinical va-
lidity. Such a mechanism will help limit duplicative efforts to
demonstrate proven clinical utility.
In its regulatory framework, the FDA has prioritized over-
sight of high-risk LDTs for “certain ID with high-risk intended
uses,” notably viral load tests for cytomegalovirus and possibly
Epstein-Barr virus and BK virus. This decision is a major con-
cern for our societies, given the enormous cost of a PMA sub-
mission. These LDTs have been in use for many years by clinical
laboratories, with well-documented data demonstrating clinical
validity and supporting their use in peer-reviewed literature. In
many cases, these LDTs have become standard of care. Our so-
cieties are happy to see the FDA is open to holding an expert
panel meeting devoted to assessing the evidence of risk for
viral load testing of transplant-associated opportunistic viral in-
fections. We urge the FDA to begin this process as soon as pos-
sible to ensure that these tests are expeditiously assessed and,
upon release of final guidance, to better reflect their moderate
risk to patients.
Improve the FDA’s Oversight Exemption for Unmet Medical Needs
While our societies applaud an exemption to LDTs for unmet
medical needs, we are concerned with the process when a com-
mercial test meeting an unmet need is approved. The 12-month
phase-in period where laboratories must submit to the FDA or
switch to a commercial test will prove difficult to laboratories,
most of which operate on a 12-month capital upgrade cycle.
Our societies fear there will be cases where laboratories will
not be able to purchase the IVD within 12 months, resulting
in a loss of capability to conduct testing for the unmet medical
need. To address this shortcoming, our societies propose a
2-year phase-in cycle.
Our societies also urge the FDA to delay oversight of LDTs
until several (3 or more) commercial tests are approved. With
only one option, laboratories may be forced to purchase expen-
sive equipment that may be used for only a single test. Delaying
oversight until several tests are available will give laboratories
much-needed flexibility to choose tests that are appropriate to
their space and cost limitations. Moreover, while the vast major-
ity of FDA-approved and cleared tests have excellent perfor-
mance characteristics, there are clear instances of tests that
identify viral resistance mutations in which LDTs have superior
performance characteristics compared with IVDs. Delaying
enforcement until multiple commercial tests are approved will
assist clinical laboratories in addressing these issues.
The FDA has indicated that, if a commercial test is used on a
specimen other than what was originally intended, that test
would be considered an LDT subject to oversight. We argue
that the need to test these nonintended specimens represents
an unmet medical need. For example, the 2010 Centers for Dis-
ease Control and Prevention sexually transmitted disease guide-
lines state that rectal and pharyngeal screening of Chlamydia
trachomatis and Neisseria gonorrhoeae must be performed by
nucleic acid amplification testing (NAAT). While commercial
NAAT IVDs exist for testing urogenital specimens for these
pathogens, there still exists the unmet need for testing rectal
or throat specimens. Our societies believe clinical laboratories
should be able to perform an analytical evaluation using a
NAAT IVD when analyzing these new specimens. We recom-
mend that the ability to test alternative sample types for these
pathogens should be the subject of enforcement discretion.
Finally, when manufacturers make improvements to tests, it
is extremely important that the process that has been created to
speed the clearance of the modified test does not limit access to
testing. For example, when adding an emerging pathogen to a
multiplexed test or making primer modifications to address
changing genetic sequences of pathogens within an assay, it is
expected that a comprehensive analytical validation will be
completed. Allowing a more limited clinical trial to be per-
formed focusing on the new pathogen or genetic modification
of the existing pathogen would make the test available to clinical
laboratories in a timely manner. Given how rapidly pathogens
emerge and evolve, lack of frequent updates is particularly prob-
lematic in the area of ID and a key factor in the need for
continued flexibility in this disease area.
Laboratory Responses to Public Health Emergencies Must Not Be
Hindered
Public health and sentinel laboratories are critical in developing
diagnostics to emerging outbreaks, including enterovirus D68,
Ebola virus disease, and Zika virus. It is paramount that LDT
oversight does not delay their ability to respond to these emerg-
ing disease threats. The FDA has indicated that LDTs to emerg-
ing diseases will be reviewed under the Emergency Use
Authorization (EUA) process. Our societies are concerned
that clinical laboratories may lack the technical, regulatory,
and clinical resources to navigate the EUA pathway in a timely
fashion. We urge the FDA to consider mechanisms to
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streamline the EUA process to account for the limited resources
available to clinical laboratories.
The FDA has also indicated that the Emergency Investiga-
tional Device Exemption pathway can be used to address public
health emergencies that do not rise to the level of an EUA,
such as chikungunya virus, novel influenza strains, or multi-
drug resistant microbial infections. However, the FDA has
only used this pathway once before, and while our societies
are cautiously supportive, it will be critical to ensure this process
does not cause undue delay in clinical laboratory responses to
an outbreak. We recommend that the FDA closely assess its
effectiveness and consider mechanisms on how it can further
streamline the review and approval process during local and
regional disease outbreaks.
Expand the Regulatory Definition of Rare Diseases for the Purposes
of LDTs
For the purposes of diagnostic tests, FDA currently defines rare
diseases as those that are tested for no more than 4000 times
each year nationwide. Rare ID present some unique challenges
to the FDA’s current definition, where encephalitis caused by
herpes simplex virus or invasive aspergillosis have symptoms
similar to widespread common infections. Therefore, they
must be tested for at far higher rates than the FDA limit of
4000 per year nationwide. The Center for Drug Evaluation
and Research at the FDA defines rare diseases, based on the
1983 Orphan Drug Act, as those that affect <200 000 patients
nationwide. IDSA, ASM, and PASCV propose that the LDT reg-
ulatory framework aligns with this definition, does not con-
strain its definition to a pathogen but rather to a disease, and
therefore permits continued enforcement discretion for LDTs
for rare diseases.
Modify the Definition of a Healthcare System to Better Reflect
Real-World Testing
While IDSA, ASM, and PASCV applaud the FDA’s carve-outs
for oversight exemptions, we are concerned that the restrictions
that preclude the testing of patients being treated at a healthcare
facility outside of the laboratory’s healthcare system will adversely
impact ID patient care. In many areas, a large institution’s clinical
laboratory may serve as a regional reference laboratory to hospi-
tals outside of its system, providing not only a quick turnaround
time for tests, but also consultations to discuss laboratory results
to ensure that appropriate clinical care decisions are made. The
FDA’s current definition of a healthcare system precludes over-
sight exemption for this use of LDTs. We urge the FDA to mod-
ify the definition of healthcare system to include instances where
local, but nonsystem, healthcare institutions interact to provide
diagnostic testing and expertise.
CONCLUSIONS
Both LDTs and commercial tests play important roles in the
care of patients with ID, and IDSA, ASM, and PASCV reiterate
that economic incentives and appropriate regulation for both
types of diagnostics are needed to ensure that patients, and
their physicians, have access to cutting-edge quality enhance-
ments in patient care. While we understand that high-risk
LDTs would likely require FDA oversight, we strongly urge
the FDA to consider exempting FDA review of moderate-risk
tests, and instead rely on third-party review by established en-
tities (eg, CAP or CLIA). We also offer the expertise of our
members to assist the FDA in developing an equitable oversight
of LDTs. Our societies hope that the final FDA oversight activ-
ities will facilitate the ever-changing needs of timely ID test
development.
Note
Potential conflicts of interest. A. M. C. reports compensation for scien-
tific advisory board participation at Roche Molecular, Abbott Molecular, bio-
Mérieux, Quidel, Cepheid, and Nanosphere. In addition, A. M. C. reports a
grant from Hologic T2 Biosystems. M. R. C. reports compensation for devel-
oping educational presentations for the Southern Central Association of Clin-
ical Microbiology and unrelated meeting expenses from Apacor. C. C. G. is
employed by bioMérieux and BioFire Diagnostics, LLC, and reports compen-
sation for consulting with GenProbe, Luminex, Medimmune, and Curetis as
well as for lecturing for GenProbe, Abbot, Curetis, and Luminex. In addition,
C. C. G. reports grants from GenProbe, Quidel, BioFire, Luminex, and
Curetis. K. E. H. reports compensation for consulting with Astellas, Cepheid,
and Biofire, and also reports grants from BioFire. M. B. M. reports compen-
sation for board participation at Cepheid; for consulting for Meridian Biosci-
ences, GenMark Diagnostics, and Becton Dickinson; and for developing
educational presentations for bioMérieux, Becton Dickinson, and Nano-
sphere. In addition, M. B. M. reports grants from Cepheid, Becton Dickinson,
Luminex Molecular Diagnostics, Nanosphere, and Hologic. All other authors
report no potential conflicts. All authors have submitted the ICMJE Form for
Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider
relevant to the content of the manuscript have been disclosed.












ealth Sciences Library user on 13 August 2019
